Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.
US-based immunotherapy developer Kleo Pharmaceuticals has been acquired by one of its investors, biopharmaceutical company Biohaven, for an undisclosed amount in an all-share deal valuing it at approximately $20m.
Founded in 2015, Kleo is working on immunotherapies that target cancerous and virally infected cells. It has treatments in development for conditions including multiple myeloma and covid-19.
The company emerged out of the laboratory of David Spiegler at Yale University. It has executed an exclusive licence with Yale for a separate…
